CD33 in Alzheimer’s Disease – Biology, Pathogenesis, and Therapeutics: A Mini-Review


Fecha de publicación: 12 December 2018


Autores: Zhao L.

Background: Alzheimer’s disease (AD) affects nearly 50 million people worldwide, and currently no disease-modifying treatment is available. With continuous failure of anti-amyloid-beta- or tau-based therapies, identification of new targets has become an urgent necessity for AD prevention and therapy. Recently, conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of AD.

Seguir leyendo

Enviar comentario